ストックスクリーナーアプリを入手
57.20
0.53%
0.303
前日終値:
$56.90
開ける：
$57.45
24時間の取引高:
2.62M
Relative Volume:
0.23
時価総額：
$116.84B
収益：
$48.48B
当期純損益:
$7.27B
株価収益率:
16.06
EPS:
3.5626
ネットキャッシュフロー:
$11.91B
1週間 パフォーマンス:
-0.12%
1か月 パフォーマンス:
+1.33%
6か月 パフォーマンス:
+9.14%
1年 パフォーマンス:
+12.85%
1日の値動き範囲:
$56.77
$57.60
1週間の範囲:
$55.26
$57.60
52週間の値動き範囲:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.22 | 116.19B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,147.00 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.16 | 573.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
225.06 | 397.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.06 | 298.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.45 | 293.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | アップグレード | UBS | Neutral → Buy |
| 2025-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-12-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 開始されました | Piper Sandler | Overweight |
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat
ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. - The Motley Fool
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest - pharmaphorum
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Links Brazil Lung Cancer Access To Long Term Story - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) Featured in Citrini's Bullish Healthcare Basket - GuruFocus
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study - Insider Monkey
Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign - Indian Pharma Post
Inside Bristol Myers’ AI-powered procurement overhaul - CFO Dive
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.00% on Jun 8: A Full Analysis - TradingKey
Disciplined Core Equity Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Competitive approach better than restricting deals with China? - BioWorld News
Bristol Myers Squibb Tests CELMoD Research for Multiple Myeloma - Koran Manado
Mariska Hargitay Partners With Bristol Myers Squibb For Cancer Campaign - Koran Manado
Mariska Hargitay Honors Dad Mickey In Bristol Myers' Myeloma Campaign 06/08/2026 - MediaPost
Bristol Myers Squibb launches myeloma awareness campaign - Investing.com
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease - 巴士的報
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease – Company AnnouncementFT.com - Financial Times
Bristol-Myers Squibb (BMY) Investor Outlook: Analyzing a Promising 10.14% Upside and 4.40% Dividend Yield - DirectorsTalk Interviews
Israel Englander Heavily Boosts Bristol Myers Squibb Position - HarianBasis.co
Assessing Bristol Myers Squibb (BMY) Valuation After Fresh EU Opdivo Approval And New Phase 3 Oncology Data - simplywall.st
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Form 11-KAnnual report of employee stock purchase, savings and similar plans - ADVFN
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Loomis Sayles Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus
Bristol Myers Squibb Adds New Late Stage Oncology Opportunity With Izalontamab - simplywall.st
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Pharma’s ‘ugly sister’ is finally ready to offer beautiful returns - Investors' Chronicle
Bristol-Myers Squibb Outperforms Earnings Expectations Amid Market Turbulence - asatunews.co.id
Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation - Yahoo Finance
Bristol Myers Squibb vs Pfizer Dividend Stock Comparison 2026News and Statistics - IndexBox
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Radiation-emitting implant improves outcomes after brain cancer surgery - Reuters
Bristol-Myers Squibb stock (US1078421011): modest move as oncology data and institutional flows draw - AD HOC NEWS
Westpac Banking Corp Purchases 46,386 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate - PMLiVE
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Motley Fool
Bank of New York Mellon Corp Has $1.32 Billion Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
0.19%
1.29%
大文字化:
|
ボリューム (24 時間):